ORPHA:565624
Combined oxidative phosphorylation defect type 39
Also known as: COXPD39 · GFM2-related combined oxidative phosphorylation defect
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
2
12.1th percentile
Trials
0
Interventional, condition-specific
Researchers
9
Distinct authors in sample
Gene link
GFM2
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare oxidative phosphorylation disorder characterized by early onset of severe (sometimes with regression of developmental milestones) and , poor or absent speech, and . Other features include movement disorder, , or microcephaly, among others. Brain imaging may show features of Leigh syndrome with signal abnormalities in the basal ganglia or mid brain, cerebellar atrophy, or thin corpus callosum.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0032726
- OMIM:618397
- UMLS:C5193075
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — GFM2
- LiteraturePresent
2 matched papers (2 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GFM2).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2
2 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2 in the last 10 years · high confidence · 12.1th percentile (publications denominator)
Phrase hits: 2 · MeSH hits: 0
Who's working on it?
9
Distinct author names in 2 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Alsentzer E1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 02Auburger G1 paper · 2022
Experimental Neurology, Medical Faculty, Goethe University, 60590 Frankfurt am Main, Germany.
Papers in Europe PMC - 03Gispert S1 paper · 2022
Experimental Neurology, Medical Faculty, Goethe University, 60590 Frankfurt am Main, Germany.
Papers in Europe PMC - 04Key J1 paper · 2022
Experimental Neurology, Medical Faculty, Goethe University, 60590 Frankfurt am Main, Germany.
Papers in Europe PMC - 05Kobren SN1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 06Kohane IS1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 07Li MM1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 08Noori A1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 09Zitnik M1 paper · 2025
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. marinka@hms.harvard.edu.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Combined oxidative phosphorylation defect type 39" OR "COXPD39" OR "GFM2-related combined oxidative phosphorylation defect"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Combined oxidative phosphorylation defect type 39" OR "COXPD39" OR "GFM2-related combined oxidative phosphorylation defect" OR "GFM2" OR "combined oxidative phosphorylation deficiency" OR "mitochondrial oxidative phosphorylation disorder"
Recall-expansion terms: GFM2, combined oxidative phosphorylation deficiency, mitochondrial oxidative phosphorylation disorder
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T18:24:01.431Z